13 February 2019
SpeeDx Develops Multiplex Test for Respiratory Viruses
SpeeDx announced submission of the PlexPCR® RespiVirus test to the Therapeutic Goods Administration (TGA), with anticipated clearance in time for the Australian 2019 flu season. The test utilises market-leading PlexPCR® multiplex technology, designed for detection of 14 targets representing 10 viral respiratory-illness causing pathogens.
“We are excited to expand our infectious disease portfolio into the respiratory market,” said Colin Denver, SpeeDx CEO.
read the full press release here.